Synthesis and biological evaluation of 2-mercapto-1,3-benzothiazole derivatives with potential antimicrobial activity

Archiv der Pharmazie

Volumn 342, Issue 10, 2009, Pages 605-613

  Franchini, Carlo ^a   Muraglia, Marilena ^a   Corbo, Filomena ^a   Florio, Marco Antonio ^a   Di Mola, Antonia ^a   Rosato, Antonio ^a   Matucci, Rosanna ^b   Nesi, Marta ^b   Van Bambeke, Francoise ^c   Vitali, Cesare ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Antibacterial activity; Benzothiazole; Efflux pump; MTS assay

Indexed keywords

2 (BENZYLSULPHANYL) 6 (1 METHYLETHYL) 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 AMINO 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 CHLORO 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 ETHOXY 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 FLUOROMETHYL 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 METHOXY 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 METHYL 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 NITRO 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL) 6 TRIFLUOROMETHYL 1,3 BENZOTHIAZOLE; 2 (BENZYLSULPHANYL)BENZOTHIAZOLE; 6 (1 METHYLETHYL) 1,3 BENZOTHIAZOLE 2 THIOL; 6 CHLORO 1,3 BENZOTHIAZOLE 2 THIOL; 6 FLUORO 1,3 BENZOTHIAZOLE 2 THIOL; 6 METHOXY 1,3 BENZOTHIAZOLE 2 THIOL; 6 METHYL 1,3 BENZOTHIAZOLE 2 THIOL; 6 TRIFLUOROMETHYL 1,3 BENZOTHIAZOLE 2 THIOL; ANTIINFECTIVE AGENT; BENZOTHIAZOLE DERIVATIVE; NORFLOXACIN; OXACILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZOTHIAZOLES; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; HELA CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349638300     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200900092     Document Type: Article

References (21)

1. M. L. Cohen, Nature 2000, 406, 762-767.
2. C. T. Barrett, J. F. Barrett, Curr. Opin. Biotechnol. 2003, 14, 621-626.
3. S. S. Andrade, R. N. Jones, A. C. Gales, H. S. Sader, J. Antimicrob. Chemother. 2003, 52, 140-141.
4. R. Finch, Clin. Microbiol. Infect. 2002, 8 (3), 21-32.
5. G. Daidone, B. Maggio, D. Schillaci, Pharmazie 1990, 45, 441-442.
6. R. D. Haugwitz, R. G. Angel, A. G. Jacobs, B. V. Maure, et al., J. Med. Chem. 1982, 25 (8), 969-974.
7. T. Hisano, M. Ichikawa, K. Tsumodo, M. Tasaki, Chem. Pharm. Bull. 1982, 30, 2996-3004.
8. H. de Wever, S. van den Neste, H. Verachter, Environ. Toxicol. Chem. 1997, 16, 843-848.
9. I. Yildiz-Oren, I. Yalcin, E. Aki-Sener, N. Ucarturk, Eur. J. Med. Chem. 2004, 39, 291-298.
10. C. N. Chaudhuri, Synth. Comm. 1996, 26, 3783-3790.
11. I. C. F. R. Ferreira, M. J. R. P. Queiroz, G. Kirsch, Tetrahedron 2003, 59, 3737-3743.
12. th ed. NCCLS document M7-A6, NCCLS, Wayne, PA 2003.
13. B. B. Ba, C. Arpin, C. Vidaillac, A. Chausse, M. C. Saux, C. Quentin, Antimicrob. Agents Chemother. 2006, 50 (6), 1931-1936.
14. S. Boyle-Vavra, R. S. Daum, Lab. Invest. 2007, 87 (1), 3-9.
15. L. J. V. Piddock, Nat. Rev. Microbiol. 2006, 4, 629-636.
16. N. P. Brenwald, M. J. Gill, R. Wise, J. Antimicrob. Chemother. 1997, 40, 458-460.
17. R. Beyer, E. Pestova, J. J. Millichap, V. Stosor, et al., Antimicrob. Agents Chemother. 2000, 44, 798-801.
18. T. Riss, R. Moravec, Promega Notes 1996, 59, 19-23.
19. W. C. Still, M. Kahn, C. Mitra, J. Org. Chem. 1978, 43, 2923-2925.
20. L. Zhu, M. Zhang, M. Dai, J. Het. Chem. 2005, 42, 727-730.
21. R. V. Kumar, K. V. S. R. S. Kumar, K. R. Gopal, J. Het. Chem. 2005, 42, 153-156.